1. Home
  2. DNOW vs MLYS Comparison

DNOW vs MLYS Comparison

Compare DNOW & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NOW Inc.

DNOW

NOW Inc.

HOLD

Current Price

$13.21

Market Cap

2.4B

Sector

Industrials

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$27.49

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DNOW
MLYS
Founded
1862
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.2B
IPO Year
2014
2023

Fundamental Metrics

Financial Performance
Metric
DNOW
MLYS
Price
$13.21
$27.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
7
Target Price
$16.67
$48.67
AVG Volume (30 Days)
3.1M
889.4K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.43
EPS
N/A
N/A
Revenue
$2,648,000,000.00
N/A
Revenue This Year
$69.47
N/A
Revenue Next Year
$8.01
N/A
P/E Ratio
N/A
N/A
Revenue Growth
25.68
N/A
52 Week Low
$10.94
$12.59
52 Week High
$17.26
$47.65

Technical Indicators

Market Signals
Indicator
DNOW
MLYS
Relative Strength Index (RSI) 56.12 47.83
Support Level $13.05 $26.01
Resistance Level $13.96 $31.12
Average True Range (ATR) 0.43 1.62
MACD -0.04 -0.29
Stochastic Oscillator 48.09 32.95

Price Performance

Historical Comparison
DNOW
MLYS

About DNOW NOW Inc.

Dnow Inc is a provider of energy and industrial solutions and a distributor of pipe, valves, and fittings (PVF) and pumps, as well as fabrication, assembly, and testing of process and production equipment. It provides a broad mix of products required to build and maintain essential infrastructure and operating equipment across upstream, midstream, gas utilities, downstream, energy transition, and industrial markets, along with value-added supply chain solutions and technical product expertise supported by digital offerings through its DigitalNOW and MRCGO e-commerce platforms. The company operates mainly under the DNOW and MRC brands and has three reportable segments: the United States, which generates the majority of revenue, Canada, and International.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: